Report cover image

Pipeline Assessment for Cardiovascular Diseases

Publisher Frost & Sullivan
Published Aug 22, 2024
SKU # MC19115518

Description

Pipeline Assessment for Cardiovascular Diseases


Advanced Drug Modalities Fuel Cardiovascular Therapeutics Future Growth Potential

Globally, CVD is the leading cause of death, with resurgence in higher-income countries and higher prevalence in low- and middle-income countries. While there have been many advancements made to this indication using wearables and advanced diagnostics and devices, growth in therapeutics has been veiled. Traditional pharmacotherapy faces the drawback of being highly invasive and causing damage to the liver, kidneys, and other organs, as well as having other side effects. In addition, cardiac surgeries are complex procedures with the possibility of postoperative complications.

For several years, small-molecule therapies have dominated cardiovascular therapies. However, they may not have uniform effectiveness in all patients; hence, targeted therapeutics are required. There was a brief period when the number of drug approvals for CVDs was lower than for other indications and drugs being developed for similar mechanisms of action; nevertheless, the industry has grown with the development of new enabling technologies that can assist the development of targeted therapies, such as gene therapies, gene editing platforms, RNA therapies, and regenerative medicine. Targeted therapies can be explored for CVDs, as some diseases (hypertrophic cardiomyopathy [HCM], for example) are caused by the MYH6 gene mutation or an abnormal protein, such as the fibroblast activation protein (FAP), in cardiac fibrosis.

This study explores the pipeline of drugs in development and emphasizes how the oldest modality, small molecules, is still being actively pursued and adopted, even amidst the growing number of gene therapies, which are likely to become the standard of care in the next 10-15 years.
The study also discusses various technological advancements, novel innovations, and the investor ecosystem. It does not include details about drug devices, diagnostic techniques, and remote monitoring technologies.

Table of Contents

    • Why Is It Increasingly Difficult to Grow?
    • The Strategic Imperative 8
    • The Impact of the Top 3 Strategic Imperatives on the Pipeline Assessment for Cardiovascular Diseases
    • Growth Opportunities Fuel the Growth Pipeline Engine
    • Research Methodology
    • Scope of Analysis
    • Segmentation
    • Growth Drivers
    • Growth Restraints
    • CVDs: An Introduction
    • CVDs: Development of Therapeutic Drugs
    • CVDs: Risk Factors
    • CVDs: Trends in Drug Development
    • Cardiovascular Therapeutics: Current Unmet Needs
    • Need for Advanced (Precision) Therapies in Cardiology
    • Small-molecule Therapeutics: A Snapshot
    • Small-molecule Therapeutics: Important Developments
    • Protein-based Therapeutics, Antibodies: A Snapshot
    • Antibodies: Important Developments
    • Protein-based Therapeutics, Peptide-based Therapies: Snapshot and Important Developments
    • Gene Therapies: A Snapshot
    • Gene Therapies: Important Developments
    • RNA Therapeutics: A Snapshot
    • RNA Therapeutics: Important Developments
    • Development of Cardiovascular Nucleic Acid Drugs
    • Regenerative Medicine in Cardiovascular Therapeutics
    • Regenerative Medicine for CVDs
    • Cardiovascular Drug Development Progress per Modality and Disease Condition
    • University Research in Cardiovascular Drug Development
    • Research Areas
    • Development of Cardiovascular Gene Therapies
    • Advances in In-vitro and In-vivo Models for CVD Modeling
    • Drug Discovery Platforms for CVDs
    • Using Omics to Accelerate Precision Medicine Development
    • Using AI in Cardiovascular Drug Discovery and Development
    • University Spin-offs Bring Innovative Therapies into the Limelight
    • Drug Development Partnerships Fuel the Process of Bringing Innovative Therapies to the Market
    • Large Pharmaceutical Companies are Actively Boosting Their Drug Pipelines Through Acquisitions
    • Growth of Funding Opportunities in the Development of Targeted Cardiovascular Therapies
    • Stakeholder Ecosystem: Key Takeaways
    • Growth Opportunity 1: Using New In-vitro Models to Quickly Translate Drugs from the Preclinical Stage to Clinical Trial Success
    • Growth Opportunity 2: Using AI/ML in Drug Discovery and Development
    • Growth Opportunity 3: Using Multi-omics to Achieve Precise CVD Treatments
    • Technology Readiness Levels (TRL): Explanation
    • Benefits and Impacts of Growth Opportunities
    • Next Steps

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us